Literature DB >> 20454897

[Central serous chorioretinopathy (CSC)].

H Baraki1, N Feltgen, J Roider, H Hoerauf, C Klatt.   

Abstract

In the acute stage central serous chorioretinopathy (CSC) is characterized by serous retinal detachment. Monofocal or multifocal structural changes of the pigment epithelium layer are common. Unilateral blurred vision is the major clinical symptom. The pathogenesis is unclear but corticosteroids and stress may trigger the disease. Normal vision often returns spontaneously within a few months. Therapeutic options are at a low evidence level. Carbonic anhydrase, mild laser photocoagulation, selective retinal therapy, photodynamic therapy and the intravitreal injection of bevacizumab have been reported. The authors suggest a treatment strategy on the basis of the available data.

Entities:  

Mesh:

Year:  2010        PMID: 20454897     DOI: 10.1007/s00347-010-2154-3

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  85 in total

1.  Indocyanine green angiography of central serous chorioretinopathy.

Authors:  K Hayashi; Y Hasegawa; T Tokoro
Journal:  Int Ophthalmol       Date:  1986-04       Impact factor: 2.031

2.  Abnormalities of fundus autofluorescence in central serous retinopathy.

Authors:  Andrea von Rückmann; Frederick W Fitzke; Joseph Fan; Anthony Halfyard; Alan C Bird
Journal:  Am J Ophthalmol       Date:  2002-06       Impact factor: 5.258

3.  Three-dimensional optical coherence tomographic findings in central serous chorioretinopathy.

Authors:  Keiichi Mitarai; Fumi Gomi; Yasuo Tano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-04-05       Impact factor: 3.117

4.  Central serous chorioretinopathy in younger and older adults.

Authors:  R F Spaide; L Campeas; A Haas; L A Yannuzzi; Y L Fisher; D R Guyer; J S Slakter; J A Sorenson; D A Orlock
Journal:  Ophthalmology       Date:  1996-12       Impact factor: 12.079

Review 5.  Type-A behavior and central serous chorioretinopathy.

Authors:  L A Yannuzzi
Journal:  Retina       Date:  1987       Impact factor: 4.256

6.  Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage.

Authors:  San-Ni Chen; Jiunn-Feng Hwang; Li-Fang Tseng; Chun-Ju Lin
Journal:  Ophthalmology       Date:  2008-12       Impact factor: 12.079

7.  Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.

Authors:  Wai-Man Chan; Timothy Y Y Lai; Ricky Y K Lai; David T L Liu; Dennis S C Lam
Journal:  Ophthalmology       Date:  2008-06-05       Impact factor: 12.079

8.  Indocyanine green angiographic findings in central serous chorioretinopathy.

Authors:  C Prünte
Journal:  Int Ophthalmol       Date:  1995       Impact factor: 2.031

9.  Central serous chorioretinopathy occurring in patients 60 years of age and older.

Authors:  H Schatz; D Madeira; R N Johnson; H R McDonald
Journal:  Ophthalmology       Date:  1992-01       Impact factor: 12.079

10.  Effect of catecholamine on central serous chorioretinopathy.

Authors:  Jinghua Sun; Junfeng Tan; Zhitao Wang; Hong Yang; Xuefei Zhu; Lingli Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2003
View more
  8 in total

1.  [Acute loss of visual acuity after pregnancy].

Authors:  Hanna Faber; Faik Gelisken
Journal:  Ophthalmologe       Date:  2020-02       Impact factor: 1.059

2.  [Spectral domain OCT in central serous chorioretinopathy: description of retinal changes].

Authors:  V Valet; C P Lohmann; M Maier
Journal:  Ophthalmologe       Date:  2012-09       Impact factor: 1.059

3.  [Treatment of central serous chorioretinopathy: MicroPulse photocoagulation versus bevacizumab].

Authors:  I Beger; M J Koss; F Koch
Journal:  Ophthalmologe       Date:  2012-12       Impact factor: 1.059

Review 4.  [Treatment of serous macular retinal detachment with antihistamines].

Authors:  K Kirschfeld
Journal:  Ophthalmologe       Date:  2015-01       Impact factor: 1.059

5.  [Uniform classification of the pachychoroid spectrum disorders].

Authors:  Alaa Din Abdin; Shady Suffo; Fabian N Fries; Hakan Kaymak; Berthold Seitz
Journal:  Ophthalmologe       Date:  2021-04-26       Impact factor: 1.059

6.  [Therapy options for chronic central serous chorioretinopathy. Photodynamic therapy combined with bevacizumab - a case series].

Authors:  M Maier; V Valet; N Feucht; C P Lohmann
Journal:  Ophthalmologe       Date:  2011-11       Impact factor: 1.059

7.  [Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy].

Authors:  M Maier; S Stumpfe; N Feucht; P Strobl; V Rath; C P Lohmann
Journal:  Ophthalmologe       Date:  2014-02       Impact factor: 1.059

Review 8.  [Central serous chorioretinopathy].

Authors:  Laurenz Pauleikhoff; Hansjürgen Agostini; Clemens Lange
Journal:  Ophthalmologe       Date:  2021-04-16       Impact factor: 1.059

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.